Anavex Life Sciences Corp. (AVXL)
NASDAQ: AVXL · Real-Time Price · USD
5.01
+0.16 (3.30%)
At close: Jan 16, 2026, 4:00 PM EST
5.06
+0.05 (1.00%)
After-hours: Jan 16, 2026, 7:52 PM EST
Anavex Life Sciences Employees
Anavex Life Sciences had 34 employees as of September 30, 2025. The number of employees decreased by 8 or -19.05% compared to the previous year.
Employees
34
Change (1Y)
-8
Growth (1Y)
-19.05%
Revenue / Employee
n/a
Profits / Employee
-$1,364,029
Market Cap
447.63M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Sep 30, 2025 | 34 | -8 | -19.05% |
| Sep 30, 2024 | 42 | 2 | 5.00% |
| Sep 30, 2023 | 40 | 2 | 5.26% |
| Sep 30, 2022 | 38 | 13 | 52.00% |
| Sep 30, 2021 | 25 | 5 | 25.00% |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
AVXL News
- 4 days ago - Anavex Life Sciences Corp. (AVXL) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 6 days ago - Anavex Joins ACCESS-AD, a Major Initiative Funded by the European Commission, Through the Clinical Evaluation of Blarcamesine as Part of a Precision Medicine Approach in Alzheimer's Disease - GlobeNewsWire
- 11 days ago - Anavex Life Sciences Appoints Senior Vice President Global Head of Neurology - GlobeNewsWire
- 13 days ago - Anavex Life Sciences Receives FDA Feedback on Alzheimer's Disease Program - GlobeNewsWire
- 25 days ago - AVXL Investors Have Opportunity to Join Anavex Life Sciences Corp. Fraud Investigation with the Schall Law Firm - GlobeNewsWire
- 4 weeks ago - Anavex Life Sciences Submitted Request for EMA to Re-Examine Its Opinion - GlobeNewsWire
- 5 weeks ago - Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer's Disease - GlobeNewsWire
- 7 weeks ago - Anavex Life Sciences to Present Oral Blarcamesine Data at the 18th Clinical Trials on Alzheimer's Disease (CTAD) Conference - GlobeNewsWire